Delivery of re‐irradiation and complex palliative radiotherapy using proton therapy in pediatric cancer patients
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30708 ↗At a glance
Journal article in Pediatric Blood & Cancer, 2023. Written by Eva Berlin and 6 co-authors. Institution: Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Re-Irradiation, Proton Therapy, Neoplasms. Cited 2 times so far (Crossref); 22 references.
Topics: Onkologische Pflege
Abstract (original language)
Background
The intent of this study is to characterize indications for pediatric palliative‐intent proton radiation therapy (PIPRT). Procedure We retrospectively reviewed patients 21 years and younger who received PIPRT. We defined PIPRT as radiotherapy (RT) aimed to improve cancer‐related symptoms/provide durable local control in the non‐curative setting. Mixed proton/photon plans were included. Adjacent re‐irradiation (reRT) was defined as a reRT volume within the incidental dose cloud of a prior RT target, whereas direct reRT was defined as in‐field overlap with prior RT target. Acute toxicity during RT until first inspection visit was graded according to the Common Terminology Criteria for Adverse Events. The Kaplan–Meier method, measured from last PIPRT fraction, was used to assess progression‐free survival (PFS) and overall survival (OS).
Results
Eighteen patients underwent PIPRT between 2014 and 2020. Median age at treatment start was 10 years [2–21]. Median follow‐up was 8.2 months [0–48]. Treatment sites included: brain/spine [10], abdomen/pelvis [3], thorax [3], and head/neck [2]. Indications for palliation included: durable tumor control [18], neurologic symptoms [4], pain [3], airway compromise [2], and great vessel compression [1]. Indications for protons included: reRT [15] (three adjacent, 12 direct), craniospinal irradiation [4], reduction of dose to normal tissues [3]. Sixteen experienced grade (G) 1–2 toxicity; two G3. There were no reports of radionecrosis. Median PFS was 5.3 months [95% confidence interval (CI): 2.7–16.3]. Median OS was 8.3 months [95% CI: 5.5–26.3].
Conclusions
The most common indication for PIPRT was reRT to provide durable tumor control. PIPRT appears to be safe, with no cases of high‐grade toxicity.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Albany Medical College, Albany Medical Center, Albany, New York, USA.
ORCID profiles: Eva Berlin, Rachel Eisenberg
Cite
APA
Berlin, E., Eisenberg, R., Hill-Kayser, C., Lustig, R. A., Kurtz, G., Cummings, E., & LaRiviere, M. (2023). Delivery of re‐irradiation and complex palliative radiotherapy using proton therapy in pediatric cancer patients. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30708
Vancouver
Berlin E, Eisenberg R, Hill-Kayser C, Lustig RA, Kurtz G, Cummings E, et al. Delivery of re‐irradiation and complex palliative radiotherapy using proton therapy in pediatric cancer patients. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30708
BibTeX
@article{Berlin2023,
author = {Berlin, Eva and Eisenberg, Rachel and Hill-Kayser, Christine and Lustig, Robert A and Kurtz, Goldie and Cummings, Elizabeth and LaRiviere, Michael},
title = {Delivery of re‐irradiation and complex palliative radiotherapy using proton therapy in pediatric cancer patients},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30708}
}
EUVIMED